Histopathological predictor of response to mirikizumab in active ulcerative colitis Successful use of mirikizumab in three patients with active ulcerative colitis was guided by clinical presentation plus high neutrophilic infiltration of the colonic epithelium (Geboes Grade 3.2).

#MedCase - Successful use of #mirikizumab in three patients with active #UlcerativeColitis was guided by clinical presentation plus high neutrophilic infiltration of the colonic epithelium (Geboes Grade 3.2).

👉 buff.ly/X3BPJaA

#GISky #GastroSky

Mirikizumab for Pediatric UC | Docwire News The phase 2 SHINE-1 trial found mirikizumab was safe and effective among pediatric patients with ulcerative colitis.

Data from the SHINE-1 trial highlight encouraging efficacy of #mirikizumab in children with #UlcerativeColitis and support its use as a potential emerging option for younger patients. #GISky #IBDSky

#MedNews - #Mirikizumab shows promising safety and efficacy in pediatric participants with moderate-to-severe active #UlcerativeColitis, the SHINE-1 study has found.

Full story 👉 buff.ly/5yfbjON

#GastroTwitter

Our 'Quote of the Week' is from Marianne Radcliffe, chief executive of Crohn's and Colitis UK, on NICE's recommendation of #mirikizumab as a treatment option for #Crohn's disease

#crohnsdisease #NICE #chronicillness
buff.ly/OkPBe85

NICE recommends mirikizumab for Crohn's disease treatment - PharmaTimes New guidance expands treatment options for eligible patients

#gastro #immunology #gastroenterology #mirikizumab #Omvoh #EliLilly #Crohnsdisease #Crohnsdiseasetreatment #NICE #NICEfinaldraftguidance #MHRA #marketingauthorisation #VIVID1clinicaltrial #clinicalremission #inflammatoryboweldisease #CrohnsandColitisUK
pharmatimes.com/news/nice-re...